Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which i

HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 20

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform C

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limitin

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints w

Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phas

Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations fro

Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analys

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Multiple patients have survived substantially beyond expected median survival, including onepatient

SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagno

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Cali

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Cal

AVAX Technologies (OTCMKTS:AVXT - Get Free Report) and Anixa Biosciences (NASDAQ: ANIX - Get Free Re

Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of

Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% o

SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a

Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c

Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c

SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")

Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExp

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, R

  On Tuesday, 647 companies set new 52-week lows.

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

  During Tuesday's session, 454 stocks hit new 52-week lows.

    Before 10 a.m. ET on Friday, 571 companies hit new 52-week highs.

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Wednesday